56Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Puerto Rico
Neuroscience Intelligence
Puerto Rico neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #49 of 50 · Data maturity A · Research score 26.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
14Recruiting trials
4Publications
8Institutions
Executive interpretation
Puerto Rico ranks #49 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Eli Lilly and Company83 recruiting
AbbVie41 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Pfizer30 recruiting
GlaxoSmithKline30 recruiting
Novartis Pharmaceuticals31 recruiting
Kodiak Sciences Inc20 recruiting
Axsome Therapeutics, Inc.20 recruiting
Merck Sharp & Dohme LLC22 recruiting
Hoffmann-La Roche20 recruiting
Disease activity
Alzheimers14trials
Pain Neuropathy6trials
Epilepsy5trials
Multiple Sclerosis5trials
Parkinsons4trials
Schizophrenia3trials
Migraine Headache3trials
Stroke2trials
Als2trials
Autism2trials
Research institutions
San Juan Bautista School of MedicineOpenAlexlinked institution
Ponce Health Sciences UniversityOpenAlexlinked institution
University of Puerto Rico at Río PiedrasOpenAlexlinked institution
Puerto Rico Department of HealthOpenAlexlinked institution
Universidad MetropolitanaOpenAlexlinked institution
University of Puerto Rico SystemOpenAlexlinked institution
University of Puerto Rico, Medical Sciences CampusOpenAlexlinked institution
University of Puerto Rico at PonceOpenAlexlinked institution
Clinical evidence trail
NCT07641517A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainRECRUITING
NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRECRUITING
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06869785Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of OfatumumabACTIVE_NOT_RECRUITING
NCT06564974Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMITRECRUITING
NCT05986292A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic PainRECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationRECRUITING
NCT05269394Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)ACTIVE_NOT_RECRUITING
NCT05125302Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RECRUITING
Research evidence trail
PUBMEDVPS13A Disease (Chorea-Acanthocytosis) in Puerto Rico; New Genetic and Clinical Observations.2026-10-16
OPENALEXMicrostimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear2006-11-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.